Mutant debrisoquine hydroxylation genes in Parkinson's disease

AETIOLOGY OF PARKINSON'S DISEASE

DonaldB. Calne, J. William Langston · The Lancet · 1983 · 466 citations

Medicine, Neurology, Neuroscience +12

ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE

André Barbeau, Madeleine Roy, S. Paris et al. · The Lancet · 1985 · 230 citations

Life Sciences, Neuroscience, Pharmacology +9

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

Rachel F. Tyndale, Toshifumi Aoyama, Franck Broly et al. · Pharmacogenetics · 1991 · 149 citations

Medicine, Biochemistry, Pharmacology +17

MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation

Raymonde Fonné‐Pfister, Mario Bargetzi, Urs Meyer · Biochemical and Biophysical Research Communications · 1987 · 129 citations

Medicine, Neuroscience, Pharmacology +16

Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.

Rachel F. Tyndale, Roger K. Sunahara, T. Inaba et al. · Molecular Pharmacology · 1991 · 126 citations

Medicine, Neuroscience, Pharmacology +15